What Happened?
Shares of life sciences company Thermo Fisher (NYSE: TMO) jumped 2.9% in the afternoon session after the company launched a new high-performance panel to accelerate neurodegenerative disease research and received a positive analyst rating.
The new product, the Olink® Target 48 Neurodegeneration panel, was designed to help researchers study diseases like Alzheimer's, multiple sclerosis, and Parkinson's by measuring key proteins from a very small sample. This innovation aimed to meet the growing need for better research tools. Further boosting investor confidence, Barclays assigned the stock an "Overweight" rating. The company also announced a partnership with India's Department for Promotion of Industry and Internal Trade to support over 500 biotech startups, a move intended to strengthen the nation's biotech sector.
After the initial pop the shares cooled down to $541.45, up 3.1% from previous close.
Is now the time to buy Thermo Fisher? Access our full analysis report here.
What Is The Market Telling Us
Thermo Fisher’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 2 days ago when the stock gained 9% on the news that the company secured a major manufacturing agreement with biotechnology firm Vaxcyte and announced a new AI-focused partnership. The agreement with Vaxcyte is valued at up to $1 billion and will provide commercial fill-finish manufacturing for its pneumococcal conjugate vaccines. This significant deal signals a strong pipeline of business for Thermo Fisher's manufacturing facilities. Adding to the positive sentiment, the company also revealed a strategic partnership with BenchSci, an AI pioneer, to develop AI-powered tools aimed at accelerating experimental design and improving R&D productivity for scientists.
Thermo Fisher is up 3.6% since the beginning of the year, but at $541.45 per share, it is still trading 10.8% below its 52-week high of $606.74 from January 2025. Investors who bought $1,000 worth of Thermo Fisher’s shares 5 years ago would now be looking at an investment worth $1,201.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.
